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Background: Radiation is a standard component of treatment for patients with locoregional recurrence (LRR) of
breast cancer following mastectomy. The current study reports the results of a 10% radiation dose escalation in
these patients.
Methods: 159 patients treated at MD Anderson Cancer Center between 1994-2006 with isolated LRR after
mastectomy alone were reviewed. Patients in the standard treatment group (65 pts, 40.9%) were treated to 50 Gy
comprehensively plus a boost of 10 Gy. The dose escalated group (94 pts, 59.1%) was treated to 54 Gy
comprehensively and a minimum 12 Gy boost. Median dose in the standard dose and dose escalated group was
60 Gy (±1 Gy, 95% CI) and 66 Gy (±0.5 Gy, 95% CI) respectively. Median follow up for living patients was 94 months
from time of recurrence.
Results: The actuarial five year locoregional control (LRC) rate was 77% for the entire study population. The five
year overall survival and disease-free survival was 55% and 41%, respectively. On multivariate analysis, initial tumor
size (p = 0.03), time to initial LRR (p = 0.03), absence of gross tumor at the time of radiation (p = 0.001) and Her2
status (p = 0.03) were associated with improved LRC. Five year LRC rates were similar in patients with a complete
response to chemotherapy without surgery and patients with a complete surgical excision (77% vs 83%, p = NS),
compared to a 63% LRC rate in patients with gross disease at the time of radiation (p = 0.024). LRC rates were 80%
in the standard dose group and 75% in the dose escalated group (p = NS).
Conclusions: While LRR following mastectomy is potentially curable, distant metastasis and local control rates
remain suboptimal. Radiation dose escalation did not appear to improve LRC. Given significant local failure rates,
these patients are good candidates for additional strategies to improve their outcomes.
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The therapeutic approaches for isolated locoregional re-
currence (LRR) of breast cancer vary widely from palli-
ation to aggressive multimodality salvage therapy. In
those patients with isolated LRR after mastectomy trea-
ted with curative intent, long-term survival ranges from
as low as 25% [1] to a more typical 50% [2-6]. The
choice of therapies is complicated by the lack of a place
in the current staging system for these patients, with* Correspondence: estrom@mdanderson.org
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reproduction in any medium, provided the ormany patients assigned a “Stage IV” designation despite
having disease that is potentially curable and without
evidence of distant metastasis. Previously, we and others
have shown that patients with isolated LRR can be
cured, but there remains considerable debate regarding
the best combination of local and systemic treatments
[2,3,7,8]. For definitive treatment, optimum management
appears to involve systemic therapy, surgical resection of
the recurrence when feasible, and post-operative radi-
ation. However, even with aggressive local therapy,
achieving durable local control is challenging [2,9,10].
In early breast cancer, dose escalation via the addition of
a tumor bed boost has been shown to result in a local con-
trol benefit [11]. Similarly, we have seen improved localLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Skinner et al. Radiation Oncology 2013, 8:13 Page 2 of 9
http://www.ro-journal.com/content/8/1/13control in inflammatory breast cancer with the use of radi-
ation dose escalation [12]. These findings led us to imple-
ment a systematic 10% radiation dose escalation in
patients treated for isolated locoregionally recurrent breast
cancer to improve on our previously reported results. The
vast majority of patients following this practice change
were treated to the higher dose, with exceptions due to
patient preference or other factors. This study compares
patient outcomes using our previous standard dose (typic-
ally 60 Gy) versus our current escalated dose (66 Gy).
Methods
After obtaining MD Anderson Cancer Center Institu-
tional Review Board (IRB) approval for a retrospective
chart analysis, a total of 292 charts was reviewed, repre-
senting all patients identified has having received radio-
therapy for loco-regionally recurrent breast cancer after
mastectomy between 1994 - 2006 at MDACC. 133
patients were excluded from this study because they had
visceral or bony metastases at time of recurrence, previ-
ous radiation to the breast or chest wall, or pathology
other than breast cancer, leaving a total of 159 patients
who were treated with curative intent. The data from
these patients were analyzed for this study.
These patients were then divided into two groups: 65
patients who were treated the lower dose and 94
patients treated using the escalated dose schema. Patient
characteristics at the time of initial diagnosis of breast
cancer, stratified by radiation treatment group are pre-
sented in Table 1. The initial surgical treatment was a
modified radical mastectomy in 141 patients (89%),
while 18 patients (11%) were treated with total mastec-
tomy and sentinel lymph node biopsy. The majority of
patients (72%) had received some form of systemic ther-
apy for their initial diagnosis of breast cancer consisting
of either hormonal therapy alone (10%), chemotherapy
alone (42%) or a combination of the two (20%). Most
patients who had not received systemic therapy at initial
diagnosis had presented with low volume (T1-T2), ER
negative and node negative disease.
All patients with recurrences in the chest wall or
reconstructed breast were treated with surgical resection
if possible. When surgical resection was not feasible,
patients were treated with systemic chemotherapy ini-
tially to downstage the tumor and allow for surgical re-
section. Patients who had a complete clinical response
to initial chemotherapy were treated with radiotherapy
alone. The majority of patients (~70%) received chemo-
therapy either prior to or after resection for their LRR.
Following resection or chemotherapy, patients were trea-
ted with radiation. Patients with ER + disease and those
with HER2+ disease frequently received hormonal ther-
apy and/or trastuzumab (if treated in the era when such
treatments were approved).The radiotherapy fields used for the treatment of re-
current disease were designed to encompass the entire
chest wall and the regional lymphatics. Several techni-
ques were used to accomplish this goal. Treatment to
the chest wall was delivered using either photon tangen-
tial fields or appositional electrons. The supraclavicular
fossa and axillary apex were treated with an anterior
photon field. A separate appositional electron field was
commonly used to treat the medial chest wall and in-
ternal mammary nodes. Although omitted by some insti-
tutions, in our practice a boost was consistently
delivered to the chest wall flaps including the scar with
generous margin and any additional sites of disease.
In the standard dose cohort, the primary radiation
fields were treated to 50 Gy followed by a 10 Gy boost
to the chest wall flaps and any additional sites of recur-
rence. The dose escalated cohort had the primary radi-
ation fields treated to 54 Gy followed by a 12 Gy boost
(Table 2).
As radiotherapy was the final aspect of multimodality
therapy for nearly all patients, all outcomes are mea-
sured from the completion date of radiotherapy. The
primary outcome was loco-regional control (LRC),
which was defined as freedom from clinical or radio-
graphic evidence of recurrence of breast cancer within
the ipsilateral chest wall, sternum or draining lymphatics
after treatment with radiation. Secondary outcomes
included overall survival (OS), disease free survival
(DFS) and distant metastasis free survival (DMFS). DFS
after radiation was defined as the interval of time with-
out LRR, distant metastasis (DM) or death following
completion of radiation. DMFS after radiation was
defined as the interval of time without distant metastasis
(DM) or death following completion of radiation. OS
after radiation was defined as the time from the comple-
tion of radiation to death. A starting point at the com-
pletion of radiation was used to create uniformity
between radiation dose groups. Median follow-up from
the time of recurrence in living patients was 108 and 92
months for standard and dose-escalated groups respect-
ively. Statistics were performed using SPSS software
(v16.0). Dose group differences were determined using
the Chi-squared statistic. The probabilities of LRC, DFS,
DMFS and OS were calculated using the Kaplan-Meier
method and log rank statistics. Univariate and multivari-
ate analysis was performed using forward step-wise Cox
regression analysis. All p values were two-sided and if
less than 0.05 were deemed significant.
Results
Outcomes for the study population
The 5 year actuarial locoregional control rate following
radiation for the entire study population was 77%, with
31/159 patients failing to secure locoregional control
Table 1 Patient characteristics at initial diagnosis of breast cancer
Dose (Gy)
All patients <66 ≥66
Median Range Median Range Median Range
Age at initial diagnosis (years) 46 25–77 47 26–77 44 25–77
Age at LRR (years) 48 25–78 50 26–78 46.5 25–77
F/U from initial diagnosis (mos) 145 6–390 140 20–382 148 6–390
F/U from XRT 94 1–218 108 1–218 92 4–164
Stage n % n % n % p-value
T1 55 34.6% 26 40.0% 29 30.9% NS
T2 76 47.8% 31 47.7% 45 47.9%
T3 14 8.8% 3 4.6% 11 11.7%
T4 7 4.4% 2 3.1% 5 5.3%
TX 7 4.4% 3 4.6% 4 4.3%
N0 81 50.9% 34 52.3% 47 50.0% NS
N1 52 32.7% 23 35.4% 29 30.9%
N2 14 8.8% 6 9.2% 8 8.5%
N3 8 5.0% 1 1.5% 7 7.4%
NX 4 2.5% 1 1.5% 3 3.2%
Primary histopathology
IDC 141 88.7% 56 86.2% 85 90.4% NS
ILC 18 11.3% 9 13.8% 9 9.6%
Tumor Grade
Well Diff 10 6.3% 2 3.1% 8 8.5% NS
Mod Diff 43 27.0% 17 26.2% 26 27.7%
Poor Diff 86 54.1% 37 56.9% 49 52.1%
Unk 20 12.6% 9 13.8% 11 11.7%
Markers
ER
Negative 70 44.0% 34 52.3% 36 38.3% 0.008
Positive 69 43.4% 19 29.2% 50 53.2%
Not done/Unknown 20 12.6% 12 18.5% 8 8.5%
PR
Negative 69 43.4% 32 49.2% 37 39.4% NS
Positive 65 40.9% 20 30.8% 45 47.9%
Not done/Unknown 25 15.7% 13 20.0% 12 12.8%
Her2
Negative 30 18.9% 10 15.4% 20 21.3% NS
Positive 15 9.4% 5 7.7% 10 10.6%
Unknown/not done 114 71.7% 50 76.9% 64 68.1%
Initial systemic therapy
Hormonal therapy only 16 10.1% 7 10.8% 9 9.6% 0.05
Chemotherapy only 66 41.5% 21 32.3% 45 47.9%
Chemotherapy and hormonal therapy 32 20.1% 11 16.9% 21 22.3%
None 45 28.3% 26 40.0% 19 20.2%
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Table 1 Patient characteristics at initial diagnosis of breast cancer (Continued)
Initial surgery
MRM 141 88.7% 59 90.8% 82 87.2% NS
Other 18 11.3% 6 9.2% 12 12.8%
Menopausal status
Pre 67 42.1% 28 43.1% 39 41.5% NS
Peri 18 11.3% 5 7.7% 13 13.8%
Post 63 39.6% 27 41.5% 36 38.3%
Unknown 11 6.9% 5 7.7% 6 6.4%
Race
Asian 11 6.9% 6 9.2% 5 5.3% NS
Black 27 17.0% 7 10.8% 20 21.3%
Hispanic 19 11.9% 11 16.9% 8 8.5%
Other 2 1.3% 1 1.5% 1 1.1%
White 100 62.9% 40 61.5% 60 63.8%
Comparison between escalated (≥66) and standard dose (<66) groups at time of initial treatment. ER positivity was significantly less in the standard dose group
(p = 0.008). No other significant differences in patient characteristics at diagnosis between groups were seen.
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subsequent recurrence following radiation included:
chest wall or reconstructed chest wall (21), sternum (2),
axilla (6), supraclavicular basin (SCV) (6), internal mam-
mary chain (IMC) (1), and infraclavicular basin (ICV)
(1) [Table 3]. Six patients had multiple sites of recur-
rence after treatment. All locoregional failures after radi-
ation occurred either in field (27 patients) or at the field
margin (4 patients). Treatment failures were occasionally
seen on the anterior abdomen, contralateral chest wall
or lymph nodes or posterior thorax, but were classified
as distant spread. On univariate analysis, multiple factors
were associated with recurrence following radiation
(Additional file 1: Table S1). However, on multivariate
analysis, only initial tumor size (p = 0.03), time to initial
recurrence (p = 0.03), clinically detectable disease at the
time of radiation (p = 0.001) and Her2 status (p = 0.03)
were associated with locoregional failure following radio-
therapy (Table 4).
Five year OS, DFS and DMFS after radiation was 55%,
41% and 44% respectively for the entire study popula-
tion, with 83 patients eventually developing distant
metastatic disease. Multiple patient and treatment fac-
tors significantly affected OS, DFS and DMFS after radi-
ation in this study on univariate analysis (Additional file
1: Table S1). For example, those patients who had a sur-
gical resection of their recurrence had significantly
improved OS (p = 0.05) and DFS (p = 0.01) after radi-
ation. However, on multivariate analysis only the pres-
ence of gross disease at the time of radiation was
uniformly predictive of poorer OS (p = 0.002), DFS (p =
0.02) and DMFS (p = 0.003). Importantly, in the 31
patients who failed locally or regionally following radi-
ation, five year OS was 27% compared to 62% in theremaining patients (p = 0.002). Also, 5 year DMFS was
significantly reduced in patients with failure following
radiation compared to those patients who achieved local
control (16% vs. 51%, p = 0.002).
The presence of gross disease as a prognostic factor
In patients with clinically apparent disease at the time of
radiation, five year LRC was 63% compared to 81% in
patients with no residual gross disease (p = 0.019). Inter-
estingly, those patients who had a clinical complete re-
sponse (CR) to chemotherapy, but no surgical resection
had comparable loco-regional control rates to those
patients whose tumor was removed by surgical excision
(77% vs. 83% p =NS). Furthermore, five year OS, DFS
and DMFS in the patients with gross disease at the time
of radiation was 34%, 19% and 21% compared to 62%,
50% and 52% in patients with no gross disease (p =
0.000007, p = 0.000007, p = 0.00002).
The impact of dose escalation on outcome
The standard and dose escalated treatment groups had no
significant differences in initial tumor or nodal stage, age
at initial diagnosis, or menopausal status (Table 1). A sig-
nificantly greater number of patients in the standard dose
group had ER-negative initial tumors (52.3% vs. 38.3%,
p = 0.007). Patients in the dose escalated group were
somewhat more likely to receive systemic therapy for their
initial diagnosis (60% vs. 79.8%, p = 0.05). Patient and
tumor characteristics at the time of loco-regional recur-
rence (LRR) are presented in Table 2 and were generally
comparable. Median time to recurrence was not signifi-
cantly different between the groups (24 vs. 34 mos). The
majority of isolated LRR were seen in the chest wall or
reconstructed chest wall either alone (62.9%) or a
Table 2 Characteristics of loco-regional recurrence of breast cancer and subsequent treatment
Dose (Gy)
All patients <66 ≥66
Median time to recurrence (mos) 26 23.5 32.0 NS
Range 2–303 5–241 2–303
Recurrence site n % N % n %
Axilla alone 12 7.5% 7 10.8% 5 5.3% NS
Reconstructed breast/CW alone 100 62.9% 39 60.0% 61 64.9%
SCV alone 12 7.5% 6 9.2% 6 6.4%
ICV alone 2 1.3% 1 1.5% 1 1.1%
IMC alone 1 0.6% 1 1.5% 0 0.0%
Sternum alone 1 0.6% 0 0.0% 1 1.1%
Reconstructed breast/CW and lymph nodes 23 14.5% 8 12.3% 15 16.0%
Multiple nodal sites 8 5.0% 3 4.6% 5 5.3%
Multiple sites of recurrence
Yes 31 19.5% 11 16.9% 20 21.3% NS
No 128 80.5% 54 83.1% 74 78.7%
Systemic therapy for recurrence
Hormones alone 34 21.4% 13 20.0% 21 22.3% NS
Chemotherapy +/- hormones 111 69.8% 45 69.2% 66 70.2%
None 12 7.5% 6 9.2% 6 6.4%
Unknown 2 1.3% 1 1.5% 1 1.1%
Surgery for recurrence
Yes 118 74.2% 51 78.5% 67 71.3% NS
No 41 25.8% 14 21.5% 27 28.7%
Gross tumor at time of radiation
Yes 42 26.4% 20 30.3% 22 26.4% NS
No 117 73.6% 45 69.2% 72 73.6%
SD SD SD
Median dose (Gy) 63.5 4.4 60.0 3.6 66.0 2.0
Median microscopic dose (Gy) 51.2 2.6 50.0 2.3 52.3 2.3
Median boost dose (Gy) 12.9 3.2 10.0 2.2 14.0 3.1
Recurrent disease and its treatment was similar in both escalated (≥66) and standard (<66) dose groups.
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No significant differences were seen between groups in
regards to site of recurrence. Similar numbers of patients
has gross residual disease at the time of radiation (30.8%
vs. 23.4%, p = NS), defined as clinical or radiographic evi-
dence of residual disease. The use of systemic chemother-
apy (69.2% vs. 70.2%, p = NS), and surgical resection
(78.5% vs. 71.3%, p =NS) was not significantly different
between the two dose groups. However, slightly more
patients in the dose escalated group received hormonal
therapy (38.5% vs. 57.4%, p = 0.05), reflecting a larger per-
centage of the population being ER-positive (24.6 vs. 43.6,
p = 0.05). Most patients (91.2%) were treated with some
form of systemic therapy, either cytotoxic chemotherapy,
hormonal therapy or a combination of the two.While radiation dose escalation was intended to im-
prove loco-regional control, LRC was 80% in the stand-
ard dose group compared to 75% in the dose escalated
group (p = 0.94). Furthermore, LRC in patients with
gross disease at the time of XRT was comparable be-
tween dose groups (56% vs. 71%, p = 0.27). LRC in
patients without gross disease was also similar between
dose groups (83% vs. 80%, p = NS).
Five year OS after radiation was 52% in the standard
dose group compared to 57% in the dose escalated group
(p = 0.29), while five year DFS was 39% in the standard
dose group compared to 43% in the dose escalated group
(p = 0.3) (Figure 1). A trend toward improved DMFS was
seen in the dose escalated patients, however this was not
significant (39% vs. 47%, p = 0.16). Nor did dose
Table 3 Subsequent recurrence after treatment for loco-
regional recurrence in breast cancer
Dose (Gy)
All patents <66 ≥66
n % n % n %
Number of patients 28 100.0% 12 42.9% 16 57.1%
Site
In Field 25 89.3% 10 35.7% 15 53.6%
Field margin 3 10.7% 2 7.1% 1 3.6%
Chest Wall 19 67.9% 8 28.6% 11 39.3%
Sternum 2 7.1% 1 3.6% 1 3.6%
Axilla 6 21.4% 4 14.3% 2 7.1%
Supraclav fossa 6 21.4% 2 7.1% 4 14.3%
Reconstructed breast 3 10.7% 1 3.6% 2 7.1%
Internal Mammary 1 3.6% 1 3.6% 0 0.0%
Infraclav fossa 1 3.6% 0 0.0% 1 3.6%
Progression during XRT 2 7.1% 1 3.6% 1 3.6%
No difference was found between escalated (≥66) and standard (<66) dose
groups in number or site of recurrences. Six patients had synchronous loco-
regional recurrences. All recurrences were either in field or at the field margin.
The sum of the anatomic sites exceeds 100% to account for simultaneous
recurrences.
Table 4 Multivariate analysis of outcomes
LRR after XRT Comparison RR p-value
•Primary diagnosis
Size Continous 1.29 0.02
•Recurrence
Time to LRR Continous 0.97 0.03
Gross tumor at XRT Yes vs. No 18.15 0.001
Her 2 status Positive vs. Negative 5.00 0.03
OS after XRT Comparison RR p-value
•Primary diagnosis
Tumor stage T2-4 vs. T1 2.54 0.001
Positive Nodes Positive vs. Negative 2.49 0.01
Nodal LRR Yes vs. No 1.96 0.05
•Recurrence
ER status Positive vs. Negative 0.37 0.005
Gross tumor at XRT Yes vs. No 1.95 0.002
DFS after XRT Comparison RR p-value
•Primary diagnosis
Percent Positive Nodes <25% vs. Negative 1.79 0.03
≥25% vs. <25% 2.73 <0.001
Tumor stage T2-4 vs. T1 2.02 0.01
•Recurrence
Gross tumor at XRT Yes vs. No 1.79 0.02
DMFS after XRT Comparison RR p-value
•Primary diagnosis
Percent Positive Nodes <25% vs. Negative 2.30 0.003
≥25% vs. <25% 3.40 <0.001
•Recurrence
Size ≥2 cm vs. < 2 cm 1.63 0.05
Gross tumor at XRT Yes vs. No 2.07 0.003
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gross disease at the time of radiation.
Complications and toxicity
Complications and toxicity directly attributable to radi-
ation were difficult to assess due to the multidisciplinary
nature of the treatment for locoregional recurrence and
the presence of pre-existing treatment effects. Complica-
tions clearly due to therapy received for the initial can-
cer diagnosis were excluded, unless this significantly
changed after completion of radiotherapy. A total of 8
patients in this study developed a grade 3 or greater
complications attributed to radiation, including one in-
stance of brachial plexopathy in each dose group and
one instance of radiation associated sarcoma in the dose
escalated group.
Discussion
Isolated loco-regional recurrence of breast cancer after
mastectomy represents several clinical challenges. The
current staging system has no mechanism to categorize
these patients and treatment approaches are not standar-
dized. Furthermore, these patients are more likely to de-
velop additional loco-regional recurrences, as well as
distant metastases, despite the best available therapy.
Complete surgical resection has typically been associated
with improved local control and overall survival [3,7,8,13],
as has post-operative radiation therapy [7,9,14]. Systemic
therapy is controversial, with at least one study showing
no benefit to the addition of chemotherapy [15]. However,many studies appear to show improved outcomes with the
addition of systemic chemotherapy [16,17] or hormonal
therapy [10,18] in this setting. In the same vein, with
improved chemotherapeutic options and patient selection,
some patients will have a complete response (CR) to
neoadjuvant systemic therapy. In these patients, data from
this study suggest that the addition of surgical excision,
with its concomitant morbidity, may not be necessary,
adding another layer of clinical complexity in an already
challenging disease.
Multi-modality therapy including systemic therapy, sur-
gery and radiation has the potential to cure selected
patients. In this study, which represents the largest single
institutional study to date, we observed a 77% locoregional
control rate and a 55% overall survival rate at 5 years. This
again highlights that aggressive local-regional therapy is
appropriate and compares favorably to the most recent







Figure 1 Survival and loco-regional recurrence after treatment for loco-regionally recurrent breast cancer. No significant difference was
seen between standard and dose-escalated groups in LRR (A), DFS (B), OS (C) or DMFS (D) after XRT.
Skinner et al. Radiation Oncology 2013, 8:13 Page 7 of 9
http://www.ro-journal.com/content/8/1/13observed that the most important predictor for any out-
come, including LRC, was the presence of residual gross
disease at the time of radiation. Local failure was high at
38% in patients with clinically apparent residual disease
and neither debulking surgery nor radiation dose escal-
ation appeared to result in improved local control. Con-
versely, patients who achieved a complete response to
chemotherapy and those with surgically resected disease
had higher rates of loco-regional control.
We were dissatisfied with the overall loco-regional
control rate in patients with isolated loco-regional recur-
rence from our last analysis of this patient cohort [2]
and we speculated that dose escalation could be useful,
as we had shown its value in inflammatory carcinoma
[12]. However, in this study we could not demonstrate a
benefit to a 10% dose escalation for isolated LRR in
breast cancer. LRC rates in both the standard and dose
escalated groups were similar with no specific subset of
patients exhibiting a benefit.
Our strategy in treating patients with isolated loco-
regionally recurrent breast cancer involves comprehensive –
as opposed to involved field – post-operative radiotherapy
in addition to systemic therapy. At least one study of LRR in
breast cancer specifically comparing treatment of the tumor
only compared to elective nodal radiation showed asignificant improvement in local control with comprehen-
sive irradiation [19]. In that study, multiple recurrences after
radiation occurred outside the original area of recurrence.
Here, however in our study all recurrences were in-field or
at the field edge suggesting the appropriateness of the field
selection and that intrinsic resistance is the primary cause
for failure to control the disease.
In regards to the patient population as a whole, a
number of indicators of poor prognosis were seen on
univariate analysis, including nodal stage at the initial
presentation as well as time to LRR after initial diagno-
sis. These factors are similar to those seen by ourselves
and others [2,6], and thus provide further verification of
their adverse effect on local control and survival out-
comes. As in primary breast cancer, lower tumor and
nodal stage, ER positivity, and smaller size of the recur-
rent tumor were all prognostic of better outcomes.
However, by far, the most significant prognostic factor
in this study was residual, clinically detectable or gross
disease at the time of radiation. Patients with gross dis-
ease at the time of radiation had dramatically poorer
locoregional control and survival outcomes than those
patients with either a complete surgical excision or a CR
to chemotherapy and dose escalation had no significant
effect on outcome. Interestingly, in patients with a CR to
Skinner et al. Radiation Oncology 2013, 8:13 Page 8 of 9
http://www.ro-journal.com/content/8/1/13chemotherapy, locoregional control rates were similar to
those in patients who were treated with a complete exci-
sion, implying surgical resection might be optional after
complete response to chemotherapy. If further surgical
resection is not an option, additional systemic therapies
including targeted agents and radiation sensitizers repre-
sent the most promising approach for those that did not
respond to chemotherapy and had gross residual disease
at the time of radiation, especially since failure to
achieve local control virtually guarantees that the patient
will subsequently develop systemic metastasis.
This study is limited by several factors inherent in all retro-
spective reviews. Although the standard and dose escalated
groups were well balanced in regards to most known factors,
confounding factors may have influenced the total dose se-
lection. In addition, only 159 total patients were reviewed.
While this represents that largest study of its kind, this num-
ber may not allow the current study to detect small differ-
ences in the outcomes measured. Further, the difference in
total dose between the two schedules is not profound. These
results must be considered hypothesis generating; however
given the unlikelihood of a randomized trial in this setting
the high rates of local failure among patients with gross re-
sidual disease at the time of radiation certainly demonstrate
room for improvement in treatment approach.
Conclusions
Locoregionally recurrent breast cancer is a potentially cur-
able disease. In this study of 159 patients we achieved 77%
locoregional control and 55% overall survival at five years
for the entire study group. In patients who could be ren-
dered free from gross disease by surgery and/or chemo-
therapy the 5-year actuarial local control rate was 81% and
the DFS rate was 50%. In the study population, radiation
dose escalation to at least 66 Gy was not sufficient to
achieve a clinically detectable improvement in loco-
regional control rates. Most failures following radiation
were in field and patients who did not achieve locoregional
control of their disease had a dismal 16% DMFS at five
years. Additionally, the presence of clinically or radiograph-
ically persistent disease at the time of radiation portends a
very low probability of control despite aggressive local and
systemic therapy. Since locoregional control remains an
important objective, we recommend studies investigating
the use of radiosensitizing agents current with radiation for
patients who are not operative candidates or who have per-
sistent disease following surgery or chemotherapy.
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